Natural combination hormone replacement formulations and therapies
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-045/00
A61K-009/48
A61K-009/16
A61K-031/57
A61K-031/565
출원번호
US-0099571
(2013-12-06)
등록번호
US-8846649
(2014-09-30)
발명자
/ 주소
Bernick, Brian A.
Cacace, Janice Louise
Persicaner, Peter H. R.
Irani, Neda
Amadio, Julia M.
출원인 / 주소
TherapeuticsMD, Inc.
대리인 / 주소
Kilpatrick Townsend & Stockton LLP
인용정보
피인용 횟수 :
10인용 특허 :
312
초록▼
Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estra
Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
대표청구항▼
1. A pharmaceutical composition comprising: solubilized estradiol;suspended progesterone;and a solubilizing agent;wherein each of the estradiol and the suspended progesterone are present in the solubilizing agent and the estradiol and progesterone are uniformly dispersed;wherein at least about 90% o
1. A pharmaceutical composition comprising: solubilized estradiol;suspended progesterone;and a solubilizing agent;wherein each of the estradiol and the suspended progesterone are present in the solubilizing agent and the estradiol and progesterone are uniformly dispersed;wherein at least about 90% of the estradiol is solubilized in the solubilizing agent; andwherein the solubilizing agent comprises an effective amount of at least one of mono-, di-, and triglycerides containing an ester of a C6-C12 fatty acid. 2. The pharmaceutical composition of claim 1, further comprising partially solubilized progesterone, wherein the partially solubilized progesterone is solubilized in the solubilizing agent. 3. The pharmaceutical composition of claim 1, wherein the formulation is formulated as a gelatin capsule. 4. The pharmaceutical composition of claim 1, wherein said estradiol has a dosage strength of at least about 0.125 mg and wherein said progesterone has a dosage strength of at least about 25 mg. 5. The pharmaceutical composition of claim 1, wherein the ratio of progesterone to estradiol is about 24:1, about 25:1, about 96:1, about 100:1, about 192:1, or about 200:1. 6. A pharmaceutical composition comprising: solubilized estradiol;suspended progesterone; anda solubilizing agent, the solubilizing agent comprising an effective amount of mono-, di-, and triglycerides containing an ester of a C6-C12 fatty acid;wherein the estradiol and the suspended progesterone are present in the solubilizing agent the estradiol and progesterone are uniformly dispersed, and at least about 90% of the estradiol is solubilized in the solubilizing agent; andwherein the estradiol does not precipitate for at least 14 days. 7. The pharmaceutical composition of claim 6, further comprising partially solubilized progesterone, wherein the partially solubilized progesterone is solubilized in the solubilizing agent. 8. The pharmaceutical composition of claim 6, wherein the composition is formulated as a gelatin capsule. 9. The pharmaceutical composition of claim 6, wherein the estradiol has a dosage strength of at least about 0.125 mg and wherein the progesterone has a dosage strength of at least about 25 mg. 10. The pharmaceutical composition of claim 6, wherein the ratio of progesterone to estradiol is about 24:1, about 25:1, about 96:1, about 100:1, about 192:1, or about 200:1. 11. A method of treating menopause symptoms of a woman with a uterus comprising: administering an effective amount of a pharmaceutical composition, the pharmaceutical composition comprising solubilized estradiol, suspended progesterone, and a solubilizing agent,wherein each of the estradiol and the suspended progesterone are present in the solubilizing agent and the estradiol and the suspended progesterone are uniformly dispersed and at least about 90% of the estradiol is solubilized in the solubilizing agent; andwherein the solubilizing agent comprises an effective amount of at least one of mono-, di-, and triglycerides containing an ester of a C6-C12 fatty acid. 12. The method of claim 11, further comprising partially solubilized progesterone, wherein the partially solubilized progesterone is solubilized in the solubilizing agent. 13. The method of claim 11, wherein the composition is formulated in a gelatin capsule. 14. The method of claim 11, wherein the estradiol has a dosage strength of at least about 0.125 mg and wherein the progesterone has a dosage strength of at least about 25 mg. 15. The method of claim 11, wherein the ratio of progesterone to estradiol is about 24:1, about 25:1, about 96:1, about 100:1, about 192:1, or about 200:1.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (312)
Hill, Edward N.; Sancilio, Frederick D.; Whittle, Robert R., (3) and (6) substitued estrogenic compounds.
Beck Lee R. (Birmingham AL) Flowers ; Jr. Charles F. (Birmingham AL) Cowsar Donald R. (Birmingham AL) Tanquary Albert C. (Birmingham AL), Active/passive immunization of the internal female reproductive organs.
Beck Lee R. (Birmingham AL) Flowers Charles F. (Birmingham AL) Cowsar Donald R. (Birmingham AL) Tanquary Albert C. (Birmingham AL), Active/passive immunization of the internal female reproductive organs.
Shih Chung ; Zentner Gaylen M., Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof.
Hawthorne M. Frederick ; Groudine Mark T., Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors.
Tracy, Timothy S.; Glover, Douglas D.; Callery, Patrick S.; Brancazio, Leo R.; McFarlin, Barbara L.; Soisson, Andrew P.; Smith, James E., Cervical drug delivery system.
Rajadhyaksha Vithal J. (27436 Esquina Mission Viejo CA 92691), Compositions and method comprising heterocyclic compounds containing two heteroatoms as membrane penetration enhancers.
Kenneth B Kirby ; Berno I. R. Pettersson, Jr., Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof.
Kirby, Kenneth B; Pettersson, Berno, Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof.
Kirby,Kenneth B; Pettersson,Berno, Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof.
Crowley ; Jr. William F. (Newtonville MA), Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for u.
Crowley ; Jr. William F. (Newtonville MA), Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for u.
Farinas Kathleen C. ; Jayalakshmi Yalia ; Lee Susanne M. ; Soni Pravin L., Crystalline form of estradiol and pharmaceutical formulations comprising same.
Wong Patrick S. L. (Palo Alto CA) Pharriss Bruce B. (Palo Alto CA), Delivery system with mated members for storing and releasing a plurality of beneficial agents.
Reed Barry Leonard,AUX ; Morgan Timothy Matthias,AUX ; Finnin Barrie Charles,AUX, Dermal penetration enhancers and drug delivery systems involving same.
Beier Sybille (Berlin DEX) Elger Walter (Berlin DEX) Nishino Yukishige (Berlin DEX) Wiechert Rudolf (Berlin DEX), Dihydrospirorenone as an antiandrogen.
Chwalisz Kristof,DEX ; Garfield Robert E., Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygena.
Hoffmann Hans-Rainer (Neuwied DEX) Klein Robert P. (Neuwied DEX) Meconi Reinhold (Neuwied DEX) Cordes Gunter (Leichingen DEX) Wolff Hans M. (Monheim DEX), Estrogen-containing active substance plaster.
Massara, Julio Eduardo; Massara, Nestor Gerardo; Dvoskin, Victor Oscar, Intravaginal devices containing progesterone for estrus synchronization and related proceses.
Massara, Julio Eduardo; Massara, Nestor Gerardo; Dvoskin, Victor Oscar, Intravaginal devices containing progesterone for estrus synchronization and related processes.
Ausiello,Dennis; Santini, Jr.,John T.; Herman,Stephen J.; Prescott,James H.; Uhland,Scott A.; Maloney,John M.; Polito,Benjamin F., Method and device for the controlled delivery of parathyroid hormone.
Maxson Wayne S. (Nashville TN) Hargrove Joel T. (Columbia TN) Meyers Philip G. (Mequon WI), Method and dosage form for treatment of premenstrual syndrome.
Virgil A. Place ; Leland F. Wilson ; Paul C. Doherty, Jr. ; Mark S. Hanamoto ; Alfred P. Spivack ; Neil Gesundheit ; Sean R. Bennett, Method for minimizing excess collagen deposition.
Plunkett Earl E.,CAX ; Wolfe Bernard M. J.,CAX, Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progesto.
Mousa, Noha Ahmed; Jebrail, Mais J.; Abdelgawad, Mohamed Omar; Wheeler, Aaron R.; Casper, Robert Fredric Joseph, Method of hormone extraction using digital microfluidics.
Coelingh Bennink, Herman Jan Tijmen; Bunschoten, Evert Johannes; Holinka, Christian Franz, Method of treating human skin and a skin care composition for use in such a method.
Spicer Darcy V. (Pasadena CA) Pike Malcolm C. (Long Beach CA), Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders.
Legrand, Valérie; Castan, Catherine; Meyrueix, Rémi; Soula, Gérard, Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles.
Berner Bret (Scarsdale NY) Ebert Charles (Salt Lake City UT) Mazzenga Gerard C. (New City NY) Otte John H. (Monsey NY), Mixed solvent mutually enhanced transdermal therapeutic system.
Maxson Wayne S. (11181 NW 26th Dr. Coral Springs FL 33065) Hargrove Joel T. (820 Hatcher La. Columbia TN 38401) Delk Joe H. (103 Cayce Valley Dr. Columbia TN 38401), Novel pharmaceutical composition containing estradiol and progesterone for oral administration.
Ahmed, Salah U.; Diliberti, Charles E.; Vattikonda, Chandra; Gorukanti, Sudhir R.; Gupta, Sanjeev K., Oral dosage forms comprising progesterone and methods of making and using the same.
Aloba, Oluwole T.; deVries, Tina M., Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation.
Aloba, Oluwole T.; deVries, Tina M, Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation.
Bunschoten, Evert Johannes; Coelingh Bennink, Herman Jan Tijmen; Van Der Linden, René Frank, Pharmaceutical application of 15- or 16-substituted testosterone analogues.
Bunschoten, Evert Johannes; Coelingh Bennink, Herman Jan Tijmen; Holinka, Christian Franz, Pharmaceutical composition for use in hormone replacement therapy.
Hill, Edward N.; Leonard, Thomas W.; Sancilio, Frederick D.; Schlipp, Katherin M.; Shirazi, Dean G.; Whittle, Robert R., Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds.
Ke,HuaZhu; Thompson,David D., Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins.
Chen,Feng Jing; Venkateshwaran,Srinivasan; Krill,Steven L.; Patel,Mahesh V., Pharmaceutical formulations and systems for improved absorption and multistage release of active agents.
Griffin, John H.; Deguchi, Hiroshi; Fernandez, Jose, Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C.
Creasy, George; O'Brien, Jr., John M.; DeFranco, Emily A.; Muse, Kenneth N., Progesterone for the treatment or prevention of spontaneous preterm birth.
Sherman Kenneth N. (135 Heather La. Wilton CT 06897) Jacobson Arnold (53 E. Altarinda Dr. Orinda CA 94563), Self administrable anti-fertility composition.
Cheng Yu-Ling (Cupertino CA) Gale Robert M. (Los Altos CA) Sugihara Edna (Mountain View CA) Sanders Harold F. (San Jose CA), Skin permeation enhancer compositions using sucrose esters.
Roser, Bruce J.; Colaco, Camilo; Jerrow, Mohammed A. Z.; Blair, Julian; Kampinga, Jaap; Wardell, James Lewis; Duffy, John Alistair, Solid delivery systems for controlled release of molecules incorporated therein and methods of making same.
Miranda Jesus (Miami FL) Sablotsky Steven (Miami FL), Solubility parameter based drug delivery system and method for altering drug saturation concentration.
Miranda Jesus (Miami FL) Sablotsky Steven (Miami FL), Solubility parameter based drug delivery system and method for altering drug saturation concentration.
Page Elliot W. (300 Country Club Heights Carmel Valley CA 93924) Rector-Page Linda G. (300 Country Club Heights Carmel Valley CA 93924), Systems and methods for the synthesis of natural base steroidal hormones and more especially estrogens and progesterone.
Setterstrom Jean A. ; Van Hamont John E. ; Reid Robert H. ; Jacob Elliot ; Jeyanthi Ramasubbu ; Boedeker Edgar C. ; McQueen Charles E. ; Jarboe Daniel L. ; Cassels Frederick ; Brown William ; Thies C, Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix.
Gale Robert M. (Los Altos CA) Enscore David J. (Sunnyvale CA) Nedberge Diane E. (Los Altos CA) Nelson Melinda (Sunnyvale CA) Cheng Yu-Ling (Cupertino CA) Libicki Shari B. (Palo Alto CA), Transdermal administration of progesterone, estradiol esters, and mixtures thereof.
Sarpotdar Pramod P. (Malvern PA) Strassburg Tammy B. (Rochester NY), Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol.
Place Virgil A. ; Wilson Leland F. ; Doherty ; Jr. Paul C. ; Hanamoto Mark S. ; Spivack Alfred P. ; Gesundheit Neil ; Bennett Sean R., Treatment of female sexual dysfunction.
Place Virgil A. ; Wilson Leland F. ; Doherty ; Jr. Paul C. ; Hanamoto Mark S. ; Spivack Alfred P. ; Gesundheit Neil ; Bennett Sean R., Treatment of female sexual dysfunction.
Virgil A. Place ; Leland F. Wilson ; Paul C. Doherty, Jr. ; Mark S. Hanamoto ; Alfred P. Spivack ; Neil Gesundheit ; Sean R. Bennett, Treatment of female sexual dysfunction using phosphodiesterase inhibitors.
Garfield Robert E. ; Chwalisz Kristof,DEX, Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combinati.
Zeun, Susan; Zimmermann, Holger; Parke, Susanne, Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido.
Bernick, Brian A.; Cacace, Janice Louise; Persicaner, Peter H. R.; Irani, Neda; Amadio, Julia M., Natural combination hormone replacement formulations and therapies.
Bernick, Brian A.; Cacace, Janice Louise; Persicaner, Peter H. R.; Irani, Neda; Amadio, Julia M., Natural combination hormone replacement formulations and therapies.
Bernick, Brian A.; Amadio, Julia M.; Persicaner, Peter H. R.; Cacace, Janice Louise; Thorsteinsson, Thorsteinn; Sancilio, Frederick D., Progesterone formulations.
Bernick, Brian A.; Amadio, Julia M.; Persicaner, Peter H. R.; Irani, Neda; Cacace, Janice Louise; Thorsteinsson, Thorsteinn; Sancilio, Frederick D., Soluble estradiol capsule for vaginal insertion.
Shadiack, Annette; Persicaner, Peter H. R.; Inskeep, Philip B.; Thorsteinsson, Thorsteinn; Sancilio, Frederick D.; Legassie, Jason D., Steroid hormone pharmaceutical composition.
Bernick, Brian A.; Amadio, Julia M.; Persicaner, Peter H. R.; Cacace, Janice Louise; Irani, Neda; Sancilio, Frederick D., Transdermal hormone replacement therapies.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.